HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells
Authors
Keywords
-
Journal
ACTA PHARMACOLOGICA SINICA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-13
DOI
10.1038/s41401-020-0399-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- SerpinB2 is involved in cellular response upon UV irradiation
- (2019) Hajnalka Majoros et al. Scientific Reports
- The Kindlin2-p53-SerpinB2 signaling axis is required for cellular senescence in breast cancer
- (2019) Khalid Sossey-Alaoui et al. Cell Death & Disease
- An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma
- (2019) Chen-Lei Wen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer
- (2019) Ke Huang et al. Cell Metabolism
- Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis
- (2018) Qian Sun et al. CELL DEATH AND DIFFERENTIATION
- Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase
- (2018) Jiang-Kai Dong et al. Theranostics
- Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells
- (2017) Jia Qu et al. JOURNAL OF CELL BIOLOGY
- SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer
- (2017) N L E Harris et al. ONCOGENE
- Low expression of SerpinB2 is associated with reduced survival in lung adenocarcinomas
- (2017) Maria Ramnefjell et al. Oncotarget
- Proteomics identification of PGAM1 as a potential therapeutic target for urothelial bladder cancer
- (2016) X.C. Peng et al. Journal of Proteomics
- Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity
- (2016) D Zhang et al. ONCOGENE
- Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions
- (2016) Song Yi Bae et al. Scientific Reports
- First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
- (2015) Y.-L. Wu et al. ANNALS OF ONCOLOGY
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer
- (2013) Zhiquan Huang et al. MOLECULAR CARCINOGENESIS
- The quest to overcome resistance to EGFR-targeted therapies in cancer
- (2013) Curtis R Chong et al. NATURE MEDICINE
- Phosphoglycerate Mutase 1 Coordinates Glycolysis and Biosynthesis to Promote Tumor Growth
- (2012) Taro Hitosugi et al. CANCER CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More